Brooke Langevin posing inside wearing a red shirt with white polka dots

Brooke Langevin, PhD

Assistant Professor of Practice, Sciences, and Health Outcomes Research

University of Maryland School of Pharmacy
Pharmacy Hall, S448

Email: brooke.langevin@rx.umaryland.edu 


Brooke Langevin, PhD, is an Assistant Professor in the Department of Practice, Sciences, and Health Outcomes Research.

Dr. Langevin is a pharmacometrician and translational scientist whose work focuses on applying quantitative modeling and simulation to inform drug development and optimize pharmacotherapy across special populations. Her research integrates population pharmacokinetics (pop-PK), physiologically based pharmacokinetic (PBPK) modeling, and data-driven decision frameworks to better understand drug exposure in populations such as pregnant individuals, infants, and patients with obesity. She brings experience across academia and industry, with a strong emphasis on advancing precision dosing and improving therapeutic outcomes through model-informed drug development.

Research Interests

  • Population and physiologically based pharmacokinetic (PK) modeling
  • Model-informed drug development and precision dosing
  • Pharmacokinetics in special populations (pregnancy, pediatrics, obesity)
  • Translational pharmacology and simulation-based decision frameworks
  • Exposure-response relationships and drug optimization

Education and Training

  • PhD: Pharmaceutical Sciences, University of Maryland, Baltimore
  • BS: Chemical and Biomolecular Engineering, Johns Hopkins University

Professional Experience

  • Assistant Professor, University of Maryland School of Pharmacy (2025–Present)
  • Graduate Research Assistant, University of Maryland School of Pharmacy (2021–2025)
  • Clinical Pharmacology Intern, AbbVie Inc.
  • Research Intern, University of Maryland School of Pharmacy
  • Pharmacometrics Intern, Janssen Pharmaceutical Companies of Johnson & Johnson

Selected Research Contributions

  • Developed population PK models to characterize drug and metabolite exposure in diverse patient populations
  • Led modeling efforts examining intergenerational transmission of low-calorie sweeteners through breast milk
  • Designed PBPK models and decision frameworks to guide pharmacokinetic studies in pregnant and obese populations
  • Conducted model-based extrapolation of drug dosing from adults to pediatric populations
  • Applied non-compartmental and nonlinear mixed effects modeling to evaluate drug distribution and exposure

Selected Publications

  • Langevin B. et al. (2023). The MILK study: Intergenerational transmission of low-calorie sweeteners. Contemporary Clinical Trials Communications.
  • Langevin B. et al. (2023). Drug prioritization framework for pharmacokinetic trials in obesity. Journal of Clinical Pharmacology.
  • Sylvetsky AC et al. (2024). Transmission of sweeteners through human milk. American Journal of Clinical Nutrition.
  • Langevin B. et al. (2023). Pharmacokinetics and biodistribution of prostaglandin E2 analogs. Radiation Research.

Teaching and Mentorship

  • Instructor for workshops on pharmacometric modeling and simulation using Pumas software
  • Teaching Assistant for multiple graduate-level pharmacometrics and pharmacokinetics courses
  • Mentor to graduate and professional students in modeling, data analysis, and translational research

Honors and Awards

  • ACOP Clinical Pharmacology SIG Award (2025)
  • ACCP Student & Trainee Abstract Awards (2020, 2023)